Cel-sci corporation reports third quarter fiscal 2022 financial results

Vienna, va.--(business wire)---- $cvm #multikine--cel-sci corporation (nyse american: cvm) today reported financial results for the quarter ended june 30, 2022, as well as key clinical and corporate developments. clinical and corporate developments include: the american society of clinical oncology (asco) published two abstracts related to cel-sci's pivotal randomized controlled phase 3 multikine® (leukocyte interleukin, injection)* head and neck cancer clinical trial for presentation at the 2022 asco annual meeti
CVM Ratings Summary
CVM Quant Ranking